Skip to main content
Premium Trial:

Request an Annual Quote

Embattled Ciphergen Hit with Second Class Action Lawsuit Alleging Fraud

NEW YORK, Dec. 7 (GenomeWeb News) - Ciphergen Biosystems was named in a second class-action lawsuit yesterday alleging that the company and certain of its officers and directors misled shareholders.

 

The latest suit, filed by the Law Offices of Charles Piven in US District Court in the northern district of California, charges that Ciphergen and certain of its top brass violated federal securities laws by "issuing a series of materially false and misleading statements to the market" between Aug. 8 and Nov. 16, according to a statement from Piven's office.

 

The suit comes one day after the law offices of Kaplan Fox & Kilsheimer sued the company in a class-action suit with essentially the same allegations. In the new case, the attorneys have not named a plaintiff and have called on Ciphergen shareholders that meet certain legal requirement to contact its office by Feb. 6, 2006.

 

As previously reported in GenomeWeb News, Ciphergen disclosed on Nov. 16 that an internal audit committee had determined that the company's second-quarter results need to be restated and could not be trusted.

 

The restatement would reduce the quarter's reported revenue by 7 percent, or $503,000, and increase reported net loss by 3 percent, or $301,000, Ciphergen said at the time.

 

The suit claims that Ciphergen's original second-quarter financial results, which reported a 10-percent slide in revenue and a 30-percent increase in losses, artificially inflated share prices, and that when the company disclosed its audit committee's findings, the stock plummeted 21percent, from $1.73 to $1.36 per share.

 

Investors who purchased Ciphergen stock between Aug. 8 and Nov. 16 are covered under class-action status.

 

Ciphergen did not immediately return a telephone call seeking comment, but in a statement today the firm said it has not responded to the suit.

 

Separately, Ciphergen today said it received a delisting notification from Nasdaq exchange because its market capital has failed to remain above $50 million for 10 consecutive days. The company received the Nasdaq letter on Dec. 2. Ciphergen has until Jan. 3, 2006, to regain compliance. The company said it will appeal the decision on Dec. 8.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.